Biotech Values

[pcrutch]

Regeneron risk/reward favorable into MEDCAC meeting, says Deutsche Bank

Deutsche Bank views the risk/reward on Regeneron (REGN) shares as favorable into today's Medicare Evidence Development & Coverage Advisory Committee meeting to review anti-VEGF treatment in diabetic macular edema, or DME. The firm notes the FDA is currently reviewing Roche's (RHHBY) Lucentis for DME and approval is expected in second half of 2012 while Regeneron's Eylea is in phase III development for DME. Deutsche thinks documents related to the meeting show concerns about Avastin's safety profile, and adds that it sees significant upside to its estimates for Regeneron should Avastin not be reimbursed for DME. [ I presume they meant Lucentis in those last 2 sentences... ]

REGN) Regeneron shares should advance in near-term, says ThinkEquity

ThinkEquity believes that the Phase I data of Regeneron's REGN727 for cholesterol management was "impressive." The firm expects the presentation of additional data by Regeneron this weekend to boost the stock further, and it reiterates a Buy rating on the shares.